Welcome to our dedicated page for BIODESIX news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on BIODESIX stock.
Biodesix, Inc. (Nasdaq: BDSX) is a diagnostic solutions company with a strong focus on lung disease and oncology, and its news flow reflects that specialization. Company updates frequently cover performance of its lung diagnostics business, including revenue trends, test volumes, and reimbursement developments for its Biodesix Diagnostic Tests marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance.
Investors and clinicians following BDSX news can expect regular financial and operating results releases, where Biodesix reports revenue from Lung Diagnostics and Development Services, discusses gross margins, and comments on measures such as Adjusted EBITDA. These announcements often describe factors influencing growth, such as increased test adoption, payer coverage, and expansion into clinical settings like pulmonology and primary care.
Biodesix also issues news about its Development Services activities and partnerships with biopharmaceutical and life sciences companies. Recent items include an expanded agreement to develop and clinically validate Droplet Digital PCR high complexity assays on Bio-Rad platforms, as well as availability of an ultra-sensitive ESR1 assay for biopharma customers and clinical use in advanced breast cancer.
Another recurring theme in BDSX news is scientific and medical conference participation. The company highlights poster presentations, workshops, and corporate events at meetings focused on lung cancer, breast cancer, pharmacoeconomics, and molecular pathology. These stories showcase new clinical utility data for Nodify Lung tests, health economic analyses of pulmonary nodule management, and research on molecular diagnostic technologies such as NGS, ddPCR, and mass spectrometry.
In addition, Biodesix reports on corporate and capital markets developments, including reverse stock split actions and Nasdaq listing compliance updates, as well as investor conference participation. For users tracking BDSX, this news page provides a centralized view of operational performance, scientific progress, collaborations, and key corporate milestones over time.
Biodesix (NASDAQ: BDSX) announced it received the 2026 USA TODAY Top Workplaces award on April 9, 2026, marking the company's third consecutive year of recognition.
The award, based on confidential employee surveys by Energage, highlights strong employee engagement, meaningful work, and a people-first culture that leadership says supports high performance and patient impact.
Biodesix (Nasdaq: BDSX) will present seven abstracts, including two oral sessions, at the AACR Annual Meeting in San Diego from April 17–22, 2026. Presentations cover blood- and tissue-based testing, tumor and immune profiling, a validated myeloid NGS panel, and multi-omic MRD pipeline development.
Highlighted technologies include mass spectrometry, Bio-Rad ddPCR, Thermo Fisher Ion AmpliSeq and Ion Torrent Genexus workflows, with partners Thermo Fisher, Bio-Rad and Memorial Sloan Kettering co-presenting MRD data.
Biodesix (Nasdaq: BDSX) announced publication of the largest lung nodule biomarker validation: a retrospective pooled analysis of 1,100 patients with 4–30 mm noncalcified nodules. The Nodify CDT test showed high specificity of 91–97% across nodule sizes, four studies and 48 US clinical practices.
Results include data from the real-world CLARIFY study (NCT06728319) and support clinical use of Nodify CDT as a decision-support tool for earlier lung cancer diagnosis.
Biodesix (NASDAQ: BDSX) reported strong Q4 2025 results with $28.8M revenue, 83% Q4 gross margin, and the company’s first-ever positive Adjusted EBITDA of $0.5M. Fiscal 2025 revenue was $88.5M (+24% YoY) and net loss improved to $35.3M.
The company finished with pro forma cash of $33.7M (including ATM), amended its term loan to November 2028, and guided FY2026 revenue to $106–112M (midpoint +23%).
Biodesix (Nasdaq: BDSX) said members of management will present at two investor conferences in March 2026: TD Cowen’s 46th Annual Health Care Conference and Barclays’ 28th Annual Global Healthcare Conference.
Fireside chats are scheduled for March 3, 2026 at 2:30 PM ET in Boston and March 11, 2026 at 12:00 PM ET in Miami, and will be webcast live with replays available on the company’s Investors site.
Biodesix (Nasdaq: BDSX) will report fourth-quarter and full-year 2025 financial results after market close on Thursday, February 26, 2026. Management will host a conference call and webcast at 4:30 p.m. Eastern Time the same day to review results and provide a business update.
A live webcast will be available with registration via the company’s investor site, a replay posted about two hours after the call, and participants are advised to join 15 minutes early.
Biodesix (Nasdaq: BDSX) reported preliminary, unaudited results for Q4 and full-year 2025. Estimated Q4 revenue $28.8M (+41% YoY) and FY2025 revenue $88.5M (+24% YoY), above prior guidance range of $84–$86M. Lung Diagnostics revenue estimated at $25.2M (Q4) and $79.2M (FY), driven by higher test volumes, price per test, and ~$1.0M in collections on claims >1 year. Test volumes were an estimated 18,000 (Q4) and 62,600 (FY). Development Services revenue was estimated at $3.6M (Q4) and $9.3M (FY). Cash and cash equivalents were ~$19.0M at 12/31/2025, including $2.3M of at-the-market proceeds. The company affirmed its expectation of positive Adjusted EBITDA in Q4 2025. Results remain preliminary and subject to audit.
Biodesix (Nasdaq: BDSX) announced poster presentations of new clinical and development data at two scientific meetings in December 2025. At NACLC (Dec 5–7, Chicago) the company will present post‑market Nodify Lung® data that address timely lung nodule risk classification and modeling of autoantibody testing impact on time to lung cancer diagnosis. At SABCS (Dec 9–12, San Antonio) Biodesix will present development data for an ultra‑sensitive ESR1 droplet digital PCR test for detecting and monitoring ESR1 variants in HR+/HER2‑ advanced breast cancer; the test is offered to biopharmaceutical customers via Development Services. The company also received two recognitions at ISPOR Europe 2025 for research on pulmonary nodule follow‑up and related healthcare costs, to be published in the December supplement of Value in Health.
Biodesix (NASDAQ: BDSX) reported Q3 2025 revenue of $21.8M, up 20% year‑over‑year, and a gross margin of 81%, a 400‑basis‑point improvement versus Q3 2024. Development Services revenue grew 97% YoY and dollars under contract reached $12.9M. The company raised full‑year 2025 revenue guidance to $84–86M and expects to reach Adjusted EBITDA positivity in Q4 2025. Q3 net loss narrowed to $8.7M; cash and equivalents were $16.6M at quarter end, impacted by a $5.2M increase in accounts receivable.
Management cited primary care expansion, payer improvements, and a Bio‑Rad partnership as drivers.
Biodesix (Nasdaq: BDSX) will present its R&D Roadmap at the 2025 AMP Annual Meeting in Boston, Nov 12-15, 2025. On Nov 12 at 4:00 PM ET, Dr. Gary Pestano will lead a Corporate Workshop on near- and longer-term diagnostic services, featuring partners Memorial Sloan Kettering Cancer Center, Bio-Rad Laboratories, and Thermo Fisher Scientific.
The workshop focuses on molecular testing advances (NGS, ddPCR, Mass Spectrometry) emphasizing rapid turn-around, high throughput, and low sample requirements; a recording will be posted on the company website. Biodesix staff will staff booth #647, and a poster on circulating tumor cell enrichment will be presented on Nov 15.